2021年4月至5月印度南部疫情期间,既往接种Covishield™和Covaxin®对有症状COVID-19患者死亡率的影响:一项队列研究
本研究为队列研究,纳入2021年4月至5月印度南部4183例RT-PCR确诊的有症状COVID-19患者,评估既往接种Covishield™或Covaxin®对死亡率等结局的影响。结果显示,全程接种者死亡率为0.2%,未接种者为12.9%;调整分析中,至少接种一剂疫苗使住院风险比(RR)为0.40(95%CI: 0.35-0.47),死亡风险比(RR)为0.18(95%CI: 0.11-0.29)。结论认为既往接种可降低疾病严重程度和死亡率,全程接种保护更强。
要点
- 全程接种者死亡率为0.2%,未接种者为12.9%。
- 至少接种一剂疫苗者死亡风险比为0.18(95%CI: 0.11-0.29)。
- 全程接种提供的保护大于部分接种。
核心结论
- 在有症状COVID-19患者中,既往接种Covishield™或Covaxin®影响了疾病严重程度,并在delta变异株广泛传播期间降低了死亡率。
- 全程接种提供的保护大于部分接种。
研究设计与样本
- 队列研究,纳入2021年4月至5月期间就诊的RT-PCR确诊的有症状COVID-19患者,共4183例。
- 评估既往接种对死亡率(主要结局)、住院需求、氧疗、无创通气(NIV)和重症监护室(ICU)入住的影响,以风险比(RR)及95%置信区间(CI)表示。
主要发现
- 队列平均(标准差)年龄为46.3(15.5)岁;17.9%(748/4183)至少接种一剂Covishield™,4.8%(201/4183)接种Covaxin®。
- 死亡率分别为:全程接种(第二剂后>2周)0.2%(95%CI: 0.2%-0.7%),部分接种(第一剂后>2周或第二剂后<2周)3.5%(1.9-5.2%),不确定接种(第一剂后<2周)6.2%(0.3-12%),未接种12.9%(11.8-14.1%)。
- 未接种与全程接种的死亡率差值为12.7%(95%CI: 11.4-13.9%),未接种与部分接种为9.4%(7.4-11.4%),未接种与不确定接种为6.8%(0.8-12.7%)。
- 调整分析中,与未接种者相比,至少接种一剂疫苗降低了住院需求(RR: 0.40; 95%CI: 0.35-0.47)、氧疗(0.33; 0.27-0.40)、NIV(0.23; 0.17-0.32)、ICU入住(0.18; 0.12-0.27)和死亡率(0.18; 0.11-0.29)。
关键数值与推荐
- 全程接种定义为第二剂后>2周,部分接种定义为第一剂后>2周或第二剂后<2周,不确定接种定义为第一剂后<2周。
- 至少接种一剂疫苗对比未接种的死亡风险比(RR)为0.18(95%CI: 0.11-0.29)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 vaccines were authorised for emergency use to mitigate the impact of the pandemic. This study evaluated the effect of prior vaccination with either Oxford Astra Zeneca's Covishield™ or Bharath Biotech's Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in India. METHODOLOGY: In this cohort study comprising of RT-PCR confirmed symptomatic COVID-19 patients presenting during April and May 2021, the effect of prior vaccination on mortality (primary outcome), need for hospitalization, oxygen therapy, non-invasive ventilation (NIV) and intensive care unit (ICU) admission were assessed and expressed as risk ratio (RR) with 95% confidence intervals (CI). RESULTS: The mean (SD) age of the cohort (n = 4183) was 46.3 (15.5) years; 17.9% (748/4183) had received at least one dose of Covishield™ and 4.8% (201/4183) had received Covaxin®. Mortality was 0.2% (95% CI: 0.2% - 0.7%), 3.5% (1.9-5.2%), 6.2% (0.3-12%) and 12.9% (11.8-14.1%) among fully vaccinated (>2 weeks after two doses), partially vaccinated (>2 weeks after one dose or <2 weeks after two doses), indeterminate (<2 weeks after one dose) and unvaccinated patients respectively. The difference in mortality among unvaccinated vs. fully vaccinated was 12.7% (95% CI: 11.4-13.9%), unvaccinated vs. partially vaccinated was 9.4% (7.4-11.4%) and unvaccinated vs. indeterminate vaccinated was 6.8% (0.8-12.7%). On adjusted analysis, as compared to unvaccinated patients, at least one dose of vaccine reduced the need for hospitalization (RR: 0.40; 95% CI: 0.35-0.47), oxygen (0.33; 0.27-0.40), NIV (0.23; 0.17-0.32), ICU admission (0.18; 0.12-0.27) and mortality (0.18; 0.11-0.29). CONCLUSION: Among symptomatic COVID-19 patients, prior vaccination with Covishield ™ or Covaxin® impacted the severity of illness and reduced mortality during a period of widespread delta variant circulation. Full vaccination conferred greater protection than partial vaccination.
引用
- Abhilash KPP, Mathiyalagan P, Krishnaraj VRK, et al. Impact of prior vaccination with CovishieldTM and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study. Vaccine. 2022. PMID: 35168837. doi:10.1016/j.vaccine.2022.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。